You can have your ambulance service compare this new one to these fourteen.
http://www.swedishwire.com/press-releases/16324-dignitana-ab-brain-cool-ab-and-university-of-edinburgh-announce-phase-one-clinical-trial
Brain Cool AB and University of Edinburgh Announce Phase One Clinical Trial to Test New Medical Brain Cooling Device.
Advanced System Holds Promise as Potentially Life-Saving Early Intervention for Stroke Patients.
LUND,
Sweden and EDINBURGH, Scotland (March 4, 2013)-Brain Cool AB announced
today that its new medical device for therapeutic brain cooling is being
tested in a clinical trial at the University of Edinburgh. Developed
initially for use with stroke patients, Brain Cool has promising
implications for use in other patient groups as well. In this University
of Edinburgh clinical trial, the device is being tested on healthy
volunteers to measure efficacy of brain cooling rates.
Brain Cool
uses a patented cooling method developed by Dignitana, a world leader
in scalp-cooling technology and the maker of the DigniCap? System for
the prevention of chemotherapy-related hair loss. The advanced
technology used in the new Brain Cool System allows cooling of the neck,
which helps to speed perfusion and cooling of blood before it reaches
the brain-a critical intervention for patients suffering from stroke.
Brain Cool is the first medical device now available for clinical use to
be tested for this purpose.
Therapeutic hypothermia, or cooling,
lowers a patient's body temperature to help reduce the risk of injury
to the brain following a period of insufficient blood flow due to an
ischemic event such as cardiac arrest, stroke, traumatic brain injury or
neonatal asphyxia. A reduction of body temperature to 35 °C induces a
kind of hibernation status of the brain that may help protect the brain
from stroke-induced damage.
"Every day 1,000 Europeans die from
stroke-that's one every 90 seconds-and about twice that number survive
but are disabled," said Dr. Malcolm Macleod, Professor of Neurology and
Translational Neuroscience and Head of experimental neuroscience at the
Centre for Clinical Brain Sciences at the University of Edinburgh.
Stroke
is the second largest cause of long-term disability in developed
countries, and the second cause of death worldwide. Even in this
advanced medical age, stroke patients today have little or no access to
immediate and effective therapy, thus, tragically, two thirds of stroke
patients remain disabled or die following a stroke.
"A further
advantage," Dr. Macleod adds, "is that cooling can be used in the vast
majority of stroke patients. This is not the case for clot-bursting
drugs, which can be used only in about one of five patients. The
technology from Brain Cool AB is particularly interesting due to the
possibility of using selective brain cooling only, and that it can be
initiated at a very early phase. In time it might be possible to
initiate brain cooling in the back of ambulances."
Results from
previous pilot studies suggest that even a small reduction of the brain
temperature-as little as 1°C, some scientists believe-could be
beneficial in treating stroke patients, and may even contribute to
significantly reduced mortality rates and improved quality of life for
stroke survivors.
"The number of patients who could potentially
be helped by brain cooling is substantial," said Martin Waleij, CEO of
Dignitana AB and Chairman of the Board for Brain Cool AB. "We expect the
findings of this clinical trial at the University of Edinburgh to
firmly confirm our pilot evaluations and provide solid clinical evidence
for the use of medical cooling primarily in stroke patients. In
addition to the indication for use in stroke, new patent applications
have also been submitted in the US complementary to the existing
worldwide patents of Dignitana AB."
Brain Cool's ease of use
provides a significantly more efficient and tolerable therapeutic
cooling method than other devices currently being tested for cooling the
brain. Unlike these other therapies, Brain Cool offers flexibility and
ease of use for both patient and clinician. The body remains completely
free and unrestricted during use, and most patients are awake or resting
calmly during treatment.
An advanced Brain Cool model that can
be easily transported is currently in development in addition to the
standard Brain Cool System now available. Portability and ease of use
could make this new medical device particularly advantageous for stroke
patients, for whom immediate intervention can be critical.
"With
nearly 150,000 people suffering a stroke each year in the UK, the
patient need for measures like brain cooling that offer protection of
the brain is obvious," adds Waleij. "Saved lives and improved quality of
life for surviving patients mean improved health and economic
gains for all of society. We are opening the door to a new world of
advanced healing that could improve quality of life for people with
stroke, traumatic brain injury, cardiac arrest, and neonatal asphyxia."
About University of Edinburgh Centre for Clinical Brain Sciences
The
Centre for Clinical Brain Sciences (CCBS) was established in 2004 and
is a part of University of Edinburgh. It is a multidisciplinary
translational "centre without walls" combining basic and applied
research to study the causes, consequences and treatment of major brain
disorders. An explicit aim of the Centre is to discover and deliver
novel therapies for brain disorders.
About Brain Cool AB (publ)
Brain
Cool AB is a wholly-owned subsidiary of Dignitana AB, with a focus on
medical cooling for therapeutic results. Brain Cool is being clinically
tested in Sweden and the United Kingdom. A patent has been filed and is
pending in the United States.
About Dignitana AB (publ)
Dignitana
AB, is a Swedish medical device company focused on innovative
technologies in the area of medical cooling. Dignitana is the creator of
DigniCap? the patented medical device for preventing hair-loss in
chemotherapy patients, which utilizes a standardized, controlled and
reliable process for cooling of the scalp in order to protect hair
follicles during chemotherapy transfusions. Dignitana is listed on the
OMX NASDAQ Stockholm First North.
No comments:
Post a Comment